Added to YB: 2026-03-10
Pitch date: 2026-03-07
CTMX [neutral]
CytomX Therapeutics, Inc.
+5.64%
current return
Author Info
AnthonyStaj shares thoughts and musings on biotech, mostly. L/S, not afraid of indication, highly focused on clinical and commercial analysis. Sign up for the newsletter.
Company Info
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
Market Cap
$793.0M
Pitch Price
$4.61
Price Target
N/A
Dividend
N/A
EV/EBITDA
23.22
P/E
19.53
EV/Sales
5.76
Sector
Biotechnology
Category
growth
CTMX: Hard work meets frustration
CTMX (deep dive): CX-2051 ADC w/ Probody masking tech targeting EpCAM achieved 28% ORR & 5.8mo PFS in 4th-line mCRC vs 1-2% ORR for approved agents (fruquintinib, regorafenib). Zero pancreatitis/hepatotoxicity validates masking platform; every prior EpCAM agent hit DLTs. Key risk: 78% diarrhea (22% G3), 1 colitis case. Q1 2026 expansion readout is binary catalyst—do not buy ahead of data. Post-data: peak US sales ~$936M at 45% share, $80K/patient. Colitis >5-10% would impair commercial profile.
Read full article (11 min)